Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver Injury

Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver Injury

Abstract Obesity and nonalcoholic fatty liver disease (NAFLD) are established risk factors for drug‐induced liver injury (DILI). The previous study demonstrates that benzbromarone (BBR), a commonly prescribed pharmaceutical agent for managing gout and hyperuricemia, exacerbates hepatic steatosis and...

Full description

Saved in:
Bibliographic Details
Main Authors: Guanting Li, Yourong Hu, Han Zhao, Ziyu Peng, Xin Shang, Jia Zhang, Kunxin Xie, Meiwei Li, Xiaohang Zhou, Qinyao Zhou, Kai Li, Fang Zhou, Heyao Wang, Zhijian Xu, Jiali Liu, Peng Sun
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Advanced Science
Subjects:
benzbromarone
drug‐induced liver injury
drug metabolism
obesity
PPARγ
Online Access:https://doi.org/10.1002/advs.202409126
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items